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Pharmacotherapy of Spasticity in Children With
Cerebral Palsy
Chia-Ying Chung,1,2* Chia-Ling Chen,1,3 Alice May-Kuen Wong1,2
Spasticity is a common disability in children with cerebral palsy. Pharmacological and non-pharmacological
treatments, including physical therapy, occupational therapy, orthotics, rhizotomy, and orthopedic sur-
gery, all play important roles in the management of spasticity. The purpose of this article is to provide an
overview of available medications for treatment of spasticity in children with cerebral palsy. Common
medications include benzodiazepines, dantrolene sodium, baclofen, tizanidine, botulinum toxins, phe-
nol, alcohol and intrathecal baclofen. In general, oral medications and intrathecal baclofen are used for
treating generalized spasticity, whilst chemodenervation agents (botulinum toxins, phenol, and alcohol)
are used to treat localized spasticity. There is more sufficient evidence for the recommendation of botu-
linum toxin A as an effective anti-spasticity treatment in children with cerebral palsy. However, more data
concerning safety and long-term effects of botulinum toxin A is needed. Further study is needed to deter-
mine which kinds of medications can cause substantial improvement in daily activity, participation level,
self-competence, or quality of life in children with cerebral palsy.
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Cerebral palsy is the most common motor disabil-
ity in childhood, with a prevalence of 2 to 2.5 per
1000 live births.1 Cerebral palsy describes a group
of disorders of movement and posture, causing
activity limitations. The activity limitations in
cerebral palsy are attributed to non-progressive
disturbance that occurs in the developing brain
of the fetus or infants. Despite advances in tech-
nology, cerebral palsy remains a clinical diagnosis,
and the essential findings include delayed motor
milestones, abnormal muscle tone, hyperreflexia
and absence of regression.2 Cerebral palsy is essen-
tially a movement and balance disorder. Children
with cerebral palsy may have muscle weakness,
spasticity, loss of coordination, and persistence of
primitive reflexes, interfering with the develop-
ment of normal motor control.3,4
In cerebral palsy, spasticity usually arises from
a chronic loss of inhibitory suprasegmental in-
puts, producing hyperactivity of the alpha motor
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neuron.5 Depending on the injury mechanism,
the manifestations of cerebral palsy may be vari-
able, with spasticity as the most common sign.6
Although spasticity is one important component
of the motor disability in cerebral palsy, it may
not be the major factor interfering with the func-
tion, participation, or activity of children.7
Spasticity Evaluation and 
Management Principles
The treatment program of spasticity begins with
careful and detailed evaluation to determine
whether muscle overactivity interferes with some
aspects of motor function. It should be deter-
mined whether the patient’s spasticity is aiding
function or not. It may be that reducing such
“useful” spasticity would be counterproductive.4
Spasticity management techniques used in chil-
dren with cerebral palsy are determined primarily
by clinical findings. The severity and distribution
of spasticity is crucial for determination of appro-
priate management.8 Spasticity in cerebral palsy
can be classified by affected body region to be
monoplegia, diplegia, hemiplegia, quadriplegia,
and double hemiplegia.4,8 It is important to doc-
ument the particular patterns and severity of
spasticity. Evaluation includes not only measure-
ment of tone with the Ashworth scale, but also one
or more measures of motor performance, func-
tional ability and health-related quality of life.4,8
The treatment plan is to maximize the active func-
tion, ease daily care, and minimize secondary prob-
lems, such as pain, joint subluxation, and joint
contracture.4 The main goal is to improve motor
and self-care ability as much as possible.
Pharmacologic treatment with antispasmodics
and non-pharmacologic treatment, such as reha-
bilitation therapy, have been mainstays in spas-
ticity management.6,8,9−12 Rehabilitation therapy
includes a wide range of techniques, such as
Bobath techniques,13,14 patterning,15 conductive
education,16 hippotherapy,17 aquatics,18 Vojta tech-
niques,19 pediatric massage,20 Adelphi Polish Suit
Program,21 and constraint-induced movement
therapy.8,22,23 The essential treatment for spastic-
ity is physical management, and all pharmaco-
logical treatment is adjunctive to good physical
management.24
Children with spastic cerebral palsy may even-
tually need orthopedic surgery to correct defor-
mity induced by muscle overactivity. However,
orthopedic surgery should be delayed until the
child’s gait is mature, usually between age 6 and
10 years, when gait analysis and clinical exami-
nation can be used to determine the need for
surgery.4 Selective dorsal rhizotomy, a surgical
intervention for the treatment of lower extremity
spasticity, may reduce the need for subsequent,
selected orthopedic interventions.25−27
Various oral, intramuscular, and intrathecal
administered medications are available to reduce
spasticity in children, which include oral benzodi-
azepines, dantrolene sodium, baclofen, tizanidine,
chemodenervation agents (such as botulinum
toxins, phenol and alcohol), and intrathecal ba-
clofen.5,28 Oral medications and intrathecal ba-
clofen are used in generalized spasticity while
chemodenervation agents are used to treat local-
ized spasticity (Table).28 In the following sections,
we give a short review covering the application of
these drugs in spasticity.
Oral Medications
Oral antispasticity medications have the advan-
tage of easy use but have the disadvantage of sys-
temic effects and significant side effects. Thus they
are most appropriate for children who need only
mild tone reduction, or who have widespread
spasticity. Most studies on the efficacy of these
medications are old, and did not have good study
designs like those used today. Therefore, the choice
of different medications is usually based on per-
sonal experience or trial and error rather than 
evidence-based medicine.4 Most oral medications,
including benzodiazepines, dantrolen, baclofen,
and tizanidine, can be used in combination with
each other. Because of the complexity of spastic-
ity, it is unlikely that one drug can be beneficial
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for all patients. The reason for combination ther-
apy is to improve the clinical effect and lessen
side effects. Oral antispasticity medications can
also be used with other treatment, such as neuro-
muscular blocking agents and intrathecal ba-
clofen. Understanding their mechanisms, side
effects and limitations is essential for treatment
of spasticity.
Benzodiazepines
Benzodiazepines are useful in reducing spasticity
because of an inhibitory effect at both the spinal
Table. Spasticity management in cerebral palsy
Therapeutic intervention Mechanisms Major points
Non-pharmacological treatment
Rehabilitation program Facilitory or inhibitory exercise program; Mainstays and cornerstones in 
training of appropriate muscles spasticity management
Casting and orthosis Extend joint range diminished by Temporary effect
hypertonicity, reduce an abnormal 
pattern by positioning
Selective posterior rhizotomy Balancing spinal-cord mediated Options for more widespread 
facilitatory and inhibitory control spasticity; permanent effect
Orthopedic surgery Correct deformity induced by Option in moderate to severe 
muscle overactivity spasticity; permanent effect
Pharmacological treatment
Oral medication
Benzodiazepines Increase the affinity of GABA for GABAA Side effects are important limiting 
receptors; inhibitory effect at both the factors for long-term use; 
spinal cord and supraspinal levels a short-term treatment
Dantrolene sodium Inhibit release of calcium from General concern regarding its 
sarcoplasmic reticulum in muscle; potential frequent and serious side 
works at the muscle effects; potential for hepatotoxicity 
in approximately 1% patients
Baclofen GABA agonist; binds at the GABAB Rapidly absorbed after oral 
receptor; Inhibit release of excitatory administration; level in the CSF are 
neurotransmitters in the spinal cord low because of low lipid solubility
Tizanidine Centrally acting alpha-2 noradrenergic Monitor liver function
agonist; inhibit release of excitatory 
neurotransmitters in the spinal cord 
and supraspinally
Chemodenervation
Alcohol/Phenol block Non-selective proteolytic agents; Cheap; when injection of a mixed 
selective denervation when injecting nerve would pose risk of 
into motor nerves or muscles painful dysesthesias
Botulinum toxin injection High affinity and specificity to the Sufficient evidence to recommend 
presynaptic membranes of as effective treatment; absence of 
cholinergic motor neurons a sensory disturbance
Intrathecal baclofen pump Using a programmable implanted Options for severe, generalized 
pump, baclofen can be delivered spasticity
intrathecally; medication can be Reversible effect
placed near the spinal cord
GABA = g-aminobutyric acid; CSF = cerebrospinal fluid.
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cord and supraspinal levels. Their effect is medi-
ated by γ-aminobutyric acid (GABA) via the GABAA
receptors.5,29 Benzodiazepines increase the affin-
ity of GABA for GABAA receptors, resulting in pre-
synaptic inhibition and a reduction of mono- and
polysynaptic reflexes. They bind in both the reticu-
lar formation and spinal polysynaptic pathways.30
Diazepam is a benzodiazepine and the oldest
antispasticity medication,5,30 with series of trials
in the 1960s demonstrating its ability to reduce
spasticity.31−34 The daily dose of diazepam is usu-
ally 0.2 to 0.8 mg/kg, divided into three or four
doses.4 Therapy is initiated as a nighttime dose to
help sleep.5 Benzodiazepines have many potential
side effects. Sedation is the most common and
may limit the clinician’s ability to increase dose.30
Ataxia, constipation, urinary retention, and weak-
ness have also been reported,5 and side effects, such
as drowsiness, sedation, hypersalivation, and weak-
ness, are important limiting factors for long term
use.28 Prolonged use of diazepam may produce
physical dependence and cannot be discontinued
abruptly.5 Therefore, it should be considered as a
short-term antispasticity treatment in children.28
Although diazepam is the most commonly used
benzodiazepine, other benzodiazepines are some-
times used in treatment of spasticity. Clonazepam
has been used to decrease night spasms.30
Dantrolene sodium
Dantrolene sodium works at the muscle, inhibit-
ing calcium release from the sarcoplasmic reticu-
lum. Studies have demonstrated that dantrolene
can reduce spasticity in children with cerebral
palsy.4,35,36 However, it can also lead to global
weakness and sedation, despite its peripheral mode
of action. Doses of dantrolene sodium in children
range up to 12 mg/kg/d. Treatment is generally
initiated at a low dose and titrated upward every
5 to 7 days as tolerated.30,37 Dantrolene sodium
also has the potential for hepatotoxicity in around
1% of patients,4,30 and may cause nausea, vomit-
ing, diarrhea or paresthesia.5,30,38 Dantrolene is
rarely used in clinical practice due to the limited
evidence to support its efficacy and the general
concerns about its serious side events.28
Baclofen
Baclofen is a GABA agonist. It can cross the blood-
brain barrier and bind to GABAB receptors of
laminae I−IV of the spinal cord, where primary
sensory fibers end,37 thereby inhibiting the re-
lease of excitatory neurotransmitters and causing
presynaptic inhibition of mono- and polysynaptic
reflexes.25,30,39 Baclofen can significantly reduce
spasticity and improved both passive and active
movement.4,40 The side effects of baclofen include
sedation, confusion, dizziness, ataxia, weakness,
nausea, hypotension, and parasthesia.25 A typical
starting dose is 2.5 mg/day, which can be titrated
up gradually to a maximum of 20 to 60 mg/day.4
However, the tendency to cause confusion and
sedation limits their clinical dose. Baclofen must
be weaned gradually to avoid a withdrawal syn-
drome.4 Acute discontinuation of both oral and
intrathecal baclofen may cause signs and symp-
toms of withdrawal, like spasticity with spasms,
hallucinations, confusion, seizures, or tempera-
ture elevation.5,41,42
Tizanidine
Tizanidine is a centrally acting alpha-2 noradren-
ergic agonist,4 and is as effective as diazepam and
baclofen in tone reduction.5,37,43 Alpha 2 adren-
ergic agonists also have an antinociceptive effect,
which may contribute to their tone-reducing abil-
ities, because pain is known to increase spasticity
in children. It is possible that this antinocicep-
tive effect is mediated through the release of sub-
stance P in the spinal cord.5,44 Tizanidine is readily
absorbed after oral administration and metabo-
lized in the liver. The half-life of tizanidine is
around 2.5 hours,30 and treatment is usually ini-
tiated as a single nighttime dose, gradually titrating
upward and adding daytime doses.30,37 Sedation
and the need for frequent dosing have been lim-
iting factors for tizanidine use. However, the
sedative effect can be an advantage when the med-
ication is given at night.4 The antispasticity effect
of tizanidine has been demonstrated in adults
with spasticity. However, little information is avail-
able to evaluate the effect of this drug in children.28
Side effects of tizanidine used in adults include
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hypotension, sedation, asthenia, dry mouth, dizzi-
ness, hallucination, and hepatotoxicity. The inci-
dence of side effects in children has not been
studied.28
Neuromuscular Blocking
Agents/chemodenervation
Chemodenervation (neurolysis or neuromuscular
blockade) usually uses injection therapy to block
neuromuscular transmission. Three techniques
are currently used, including perineural injec-
tion of phenol,4,45,46 or ethyl alcohol,8,47,48 and 
intramuscular injection of botulinum toxin.49−52
Injectable neuromuscular blocking agents can
balance muscle power across joints by producing
selective denervation of muscles and nerves.8
Injection therapy to block neuromuscular trans-
mission is mainly applied for treating focal spas-
ticity. The duration of the effect depends on the
agent and sites of injection.
Botulinum toxins A and B
Numerous retrospective or prospective studies
have described the potency of botulinum toxin A
to reduce the spasticity in children with cerebral
palsy.49−53 Botulinum toxin A is a major break-
through in the treatment of spasticity. It is effective
in reducing spasticity and provides a time-limited
improvement in motor function of the extremities
for children with cerebral palsy.6
Botulinum toxin A works at the neuromuscular
junction by inhibiting the release of acetylcholine.
It binds, with high affinity and specificity, to
presynaptic membranes of cholinergic motor neu-
rons, and is then internalized; thereby preventing
the discharge of acetylcholine-containing vesicles.50
For localized spasticity that needs treatment, bot-
ulinum toxin A can be injected intramuscularly to
produce selective and reversible chemodenerva-
tion at the neuromuscular junction. Typically, there
is a 3 to 4 month clinical response period requir-
ing repeated injections of the agent. Some stud-
ies suggest using the smallest dose of botulinum
toxin A and avoiding injections more frequently
than every 3 months to minimize the risk of 
antibody resistance.4,28 Failure to respond to these
injections may indicate the production of anti-
bodies against botulinum toxin A, which may
develop in around 5% of patients.25,54 Modifying
drug preparations, accurate target muscle injection
and combination therapy with other adjunctive
therapy have been emphasized for better efficacy
and reduction of drug resistance.
Botulinum toxin A has an excellent safety pro-
file with a low incidence of side effects. Commonly
reported side effects include muscle soreness, pain,
leg cramps, skin rash, fatigue, excessive weakness,
calf atrophy, influenza-like symptoms, infection,
bleeding and allergic reaction.5,8,55 Systemic effects,
such as dysphagia, dysphonia, weakness, dyspnea,
or respiratory distress, have also been reported as
potential side effects.28
Chemical denervation
Phenol and alcohol are non-selective proteolytic
agents and can produce selective denervation
when injected into motor nerves or muscles.8 In
general, 45−50% of alcohol solution, diluted
with normal saline, is used for injection to motor
nerves and muscle.47,48 The duration of denerva-
tion with alcohol injection is about 3−6 months.8
Phenol is the most commonly used agent to
produce chemical neurolysis. The duration of
denervation of phenol is about 4−8 months.8
Injections of 3 to 5−6% of phenol solution per-
ineurally promotes denervation via axonal de-
generation,4,25 or into motor points of selected
muscles produces a sustained reduction in mus-
cle tone.25 The target nerve is usually identified
with electrical stimulation, a procedure that may
be poorly tolerated in children, requiring seda-
tion or anesthesia.4 Phenol can denature proteins
when injected perineurally, disrupting efferent
signals from hyperexcitable anterior horn cells
by inducing necrosis of the axons.25,56,57 The ef-
fect of denervation is not permanent, with func-
tional reinervation occurring in months to years.4
Studies have demonstrated the benefits of alco-
hol47,48 and phenol45,46 in treating spasticity in
cerebral palsy. Side effects of phenol block include
C.Y. Chung, et al
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lethargy and nausea secondary to systemic ab-
sorption, dysesthesia due to necrosis of sensory
axons, possible permanent muscle fibrosis,8 and
the potential for necrosis of skin at the injection
site.57 Neurolysis may also lead to pain, especially
when mixed nerves are treated. Despite these lim-
itations, the low cost of phenol makes phenol 
injections a good treatment choice in selected
patients with focal spasticity.25 The absence of
immunogenicity and the lower cost compared
with botulinum toxins make these agents more
attractive in some institutes.4,58
Intrathecal Baclofen
By contrast to botulinum toxins, intrathecal ba-
clofen and selective dorsal rhizotomy are used to
manage more widespread spasticity.8
Baclofen is hydrophilic and its low lipid solu-
bility limits its transport across the blood-brain
barrier. Contrastingly, spinal intrathecal baclofen
administration can bypass the blood-brain barrier.
By infusing baclofen directly into the subarach-
noid space around the spinal cord, the GABA-
mediated inhibition of spasticity can be achieved
while minimizing the side effects secondary to
high level of baclofen in the brain.25 Baclofen
has its effect by binding with GABAB receptors in
the spinal cord. Since the site of action is in the
spinal cord, intrathecal baclofen administration
can have a much lower incidence of cerebral side
effects and often a higher reduction in muscle
tone than when administered orally.30,59,60 The
effectiveness of oral baclofen has been limited by
its sedating side effect. It has been reported that
the intrathecal dose of baclofen is only 1% of the
oral dose.30,61 The half-life of intrathecal baclofen
in the cerebrospinal fluid is about 5 hours.30,62
However, the short half-life of the drug means
continuous infusion is necessary for better spas-
ticity reduction.8,62 Intrathecal baclofen is an ef-
fective treatment for severe, generalized spasticity
in selected patients with cerebral palsy and move-
ment disorders.8,25 However, patients must be 
of sufficient size to fit the pump, so typically a
minimum of 15 kg is needed.25 As with other im-
planted devices, complications of intrathecal ba-
clofen administration are possible.30,59,61,63 These
complications may be secondary to surgical com-
plications, human error or device-related com-
plications. Infection rates reported in the literature
vary, but may be about 5%. Overdose has been
reported, secondary to human errors in program-
ming or refilling pump procedures. Depending
on the degree of overdose, respiratory suppres-
sion and reversible changes in consciousness may
occur.30 Technical problems related to the infu-
sion system have also been reported to occur
around 1% per year of service. The majority of
these technical problems involves breakage or
disconnection of the catheter.25,60 Catheter or
pump failure may lead to a sudden withdrawal
of medication, causing signs and symptoms of
withdrawal. There have been reports of spasticity,
hallucination, temperature elevation, confusion,
or seizures associated with sudden withdrawal of
intrathecal baclofen.5 Drug-related side effects
include changes in bowel or bladder function,
impotence, sedation, dizziness, weakness, nausea,
and vomiting.61
Conclusion
Muscle overactivity can be a significant source 
of functional disability in children with cerebral
palsy. Appropriate treatment can improve the
function, reduce pain, and prevent or correct 
deformity. Oral medications, chemodenervation,
rhizotomy, intrathecal baclofen, and orthopedic
surgery may all play important roles in the prop-
erly selected children. Although physical and oc-
cupational therapy is central to any treatment plan,
oral antispasticity agents have the advantages of
easy use but the disadvantages of systemic effects.
In general, oral medications have narrow thera-
peutic windows, and are used when generalized
spasticity is noted. However, most studies on the
efficacy of oral antispasticity agents are old, and
deserve serious research effort. Chemodenerva-
tion, including botulinum toxin A, phenol and
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alcohol, is the main option for treating focal
spasticity. The effect is temporary. However, phe-
nol and alcohol can be used in combination with
botulinum toxin A once the maximum dosage of
botulinum toxin A is met. There is sufficient evi-
dence to support the use of botulinum toxin A as
an effective antispasticity treatment. Intrathecal
baclofen is used to manage more widespread spas-
ticity. By considering whether the intervention 
is focal or generalized in effect and whether the
effect is permanent or temporary, appropriate
choices of antispasticity treatment can be made.
For successful management, the least invasive and
most cost-effective treatment should be chosen.
More evidence is needed to determine which
medications can make substantial improvement
in daily activity, participation level, or quality of
life in children with cerebral palsy.
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